These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The case for lipid control. Lipold AG Bus Health; 2001 Dec; 19(12 Suppl A):12-5. PubMed ID: 11799636 [No Abstract] [Full Text] [Related]
4. Targeting levels and functions of blood lipids in the prevention of CVD. Mearns BM Nat Rev Cardiol; 2011 Apr; 8(4):179-80. PubMed ID: 21436841 [No Abstract] [Full Text] [Related]
5. [Primary prevention of cardiovascular diseases by lowering lipids]. Klose G Internist (Berl); 1997 Jun; 38(6):615-6. PubMed ID: 9265009 [No Abstract] [Full Text] [Related]
6. The editor's roundtable: expanded versus standard lipid panels in assessing and managing cardiovascular risk. Sulkes D; Brown BG; Krauss RM; Segrest JP; Sniderman AD; Roberts WC Am J Cardiol; 2008 Mar; 101(6):828-42. PubMed ID: 18328849 [No Abstract] [Full Text] [Related]
7. The Ideal Lipid Report: A Need for Consensus. Pedro-Botet J; Rodríguez-Padial L; Brotons C; Esteban-Salán M; García-Lerín A; Pintó X; Lekuona I; Ordóñez-Llanos J Rev Esp Cardiol (Engl Ed); 2018 Jul; 71(7):512-514. PubMed ID: 29716842 [No Abstract] [Full Text] [Related]
8. [The effect of short-term regular exercise-diet programs on the lipid profile in sedentary subjects]. Umman B; Bilge AK Anadolu Kardiyol Derg; 2001 Dec; 1(4):272-5. PubMed ID: 12101837 [No Abstract] [Full Text] [Related]
9. Investigation of lipids. What do the results really mean? Sullivan D Aust Fam Physician; 2000 Mar; 29(3):207-11. PubMed ID: 10785985 [TBL] [Abstract][Full Text] [Related]
10. [Pathophysiologic aspects of hyperlipoproteinemias]. Soska V Vnitr Lek; 2000 Sep; 46(9):506-9. PubMed ID: 11344641 [TBL] [Abstract][Full Text] [Related]
11. Tibolone and the serum lipid/lipoprotein profile: does this have a role in cardiovascular protection in postmenopausal women? Ginsburg J; Prelevic GM Menopause; 1999; 6(2):87-9. PubMed ID: 10374212 [No Abstract] [Full Text] [Related]
12. Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease. Lardizabal JA; Deedwania P Cardiol Clin; 2011 Feb; 29(1):87-103. PubMed ID: 21257102 [TBL] [Abstract][Full Text] [Related]
15. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents]. Soska V Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414 [TBL] [Abstract][Full Text] [Related]
16. [The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome]. Millán Núñez-Cortés J; Montoya JP; Salas XP; Hernández Mijares A; Carey VJ; Hermans MP; Sacks FM; Fruchart JC Endocrinol Nutr; 2011 Jan; 58(1):38-47. PubMed ID: 21208833 [TBL] [Abstract][Full Text] [Related]
17. Do we need a fasting lipid profile to assess cardiovascular risk? Grunberger G J Diabetes; 2011 Sep; 3(3):172-3. PubMed ID: 21668658 [No Abstract] [Full Text] [Related]